Optic Neuritis: An Update. II. Optic Neuritis and Multiple Sclerosis

REFERENCES

• Hickman S J, Dalton C M, Miller D H, et al. Management of acute optic neuritis. Lancet. 2002; 360: 1953–1962
   PubMed Web of Science ®Google Scholar
• Plant G T. Optic neuritis and multiple sclerosis. Curr Opin Neurol 2008; 21: 16–21
   Web of Science ®Google Scholar
• Kidd D P, Plant G T. Optic Neuritis. Neuro-Ophthalmology, D P Kidd, N J Newman, V Biousse. Butterworth-Heinemann, Philadelphia 2008; 134–152
   Google Scholar
• The Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: Final Optic Neuritis Treatment Trial follow-up. Arch Neurol. 2008; 65: 727–732
   PubMed Web of Science ®Google Scholar
• Fisniku L K, Brex P A, Altmann D R, et al. Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131: 808–817
   PubMed Web of Science ®Google Scholar
• Beck R W, Cleary P A, Trobe J D, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med. 1993; 329: 1764–1769
   PubMed Web of Science ®Google Scholar
• Clerico M, Faggiano F, Palace J, et al. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database of Systematic Reviews. 2008, Issue 2. Art. No.: CD005278
   Google Scholar
• Galetta S L, Plant G T. Interferon beta in acute optic neuritis. Neuro-Ophthalmol. 2006; 30: 41–51
   Web of Science ®Google Scholar
• Hickman S J, Ko M, Chaudhry F, Jay W M, Plant G T. Optic neuritis: An update. (1) Typical and atypical optic neuritis. Neuro-Ophthalmoly. 2008; 32: 237–248
   Web of Science ®Google Scholar
• McAlpine D. Multiple sclerosis: A review. Br Med J. 1973; 2: 292–295
   PubMed Web of Science ®Google Scholar
• McAlpine D, Lumsden C E, Acheson ED. Multiple sclerosis: A reappraisal. 2nd ed, , et al. Churchill Livingstone, Edinburgh 1972
   Google Scholar
• Alter M, Good J, Okihiro M. Optic neuritis in Orientals and Caucasians. Neurology 1973; 23: 631–639
   Google Scholar
• Rizzo J F, 3rd, Lessell S. Risk of developing multiple sclerosis after uncomplicated optic neuritis: A long-term prospective study. Neurology 1988; 38: 185–190
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Siva A, Cross S A, et al. Optic neuritis: A population-based study in Olmsted County, Minnesota. Neurology 1995; 45: 244–250
   PubMed Web of Science ®Google Scholar
• Jacobs L D, Kaba S E, Miller C M, et al. Correlation of clinical, magnetic resonance imaging, and cerebrospina1 fluid findings in optic neuritis. Ann Neurol. 1997; 41: 392–398
   PubMed Web of Science ®Google Scholar
• Hutchinson W M. Acute optic neuritis and the prognosis for multiple sclerosis. J Neurol Neurosurg Psychiatry. 1976; 39: 283–289
   PubMed Web of Science ®Google Scholar
• Druschky A, Heckmann J G, Claus D, et al. Progression of optic neuritis to multiple sclerosis: An 8-year follow-up study. Clin Neurol Neurosurg. 1999; 101: 189–192
   Google Scholar
• Ghezzi A, Martinelli V, Torri V. Longterm followup of isolated optic neuritis: The risk of developing multiple sclerosis, its outcome and the prognostic role of paraclinical tests. J Neurol. 1999; 246: 770–775
   PubMed Web of Science ®Google Scholar
• Kinnunen E. The incidence of optic neuritis and its prognosis for multiple sclerosis. Acta Neurol Scand. 1983; 68: 371–377
   PubMed Web of Science ®Google Scholar
• Söderström M, Ya-Ping J, Hillert J, et al. Optic neuritis: Prognosis for multiple sclerosis from MRI, CSF and HLA findings. Neurology 1998; 50: 708–714
   PubMed Web of Science ®Google Scholar
• Bojić L, Rogošić V, Ivanišević M, et al. Progression of optic neuritis to multiple sclerosis in the county of Split-Dalmatia, Croatia. Coll Anthropol. 2007; 31: 557–560
   Google Scholar
• Kahana E, Alter M, Feldman S. Optic neuritis in relation to multiple sclerosis. J Neurol. 1976; 213: 87–95
   PubMed Web of Science ®Google Scholar
• Amirzargara A A, Tabasib A, Khosravia F, et al. Optic neuritis, multiple sclerosis and human leukocyte antigen: Results of a 4-year follow-up study. Eur J Neurol. 2005; 12: 25–30
   Google Scholar
• Lin Y-C, Yen M-Y, Hsu W-M, et al. Low conversion rate to multiple sclerosis in idiopathic optic neuritis patients in Taiwan. Jpn J Ophthalmol. 2006; 50: 170–175
   PubMed Web of Science ®Google Scholar
• Isayama Y, Takahashi T, Shimoyoma T, et al. Acute optic neuritis and multiple sclerosis. Neurology 1982; 32: 73–76
   PubMed Web of Science ®Google Scholar
• Frith J A, McLeod J G, Hely M. Acute optic neuritis in Australia: A 13 year prospective study. J Neurol Neurosurg Psychiatry. 2000; 68: 246–256
   PubMed Web of Science ®Google Scholar
• Corona-Vazquez T, Ruiz-Sandoval J, Arriada-Mendicoa N. Optic neuritis progressing to multiple sclerosis. Acta Neurol Scand. 1997; 95: 85–89
   PubMed Web of Science ®Google Scholar
• Alvarez G, Cardenas M. Multiple sclerosis following optic neuritis in Chile. J Neurol Neurosurg Psychiatry. 1989; 52: 115–117
   PubMed Web of Science ®Google Scholar
• Lana-Peixoto M A, Lana-Peixoto M I. The risk of multiple sclerosis developing in patients with isolated idiopathic optic neuritis in Brazil. Arq Neuro-Psiquiat (São Paulo) 1991; 49: 377–383
   Google Scholar
• Ebers G C. Environmental factors and multiple sclerosis. Lancet Neurol. 2008; 7: 268–277
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet. 2002; 359: 1221–1231
   PubMed Web of Science ®Google Scholar
• Ramsaransing G, Maurits N, Zwanikken C, De Keyser J. Early prediction of a benign course of multiple sclerosis on clinical grounds: A systematic review. Mult Scler. 2001; 7: 345–347
   PubMedGoogle Scholar
• Kurtzke J F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452
   PubMed Web of Science ®Google Scholar
• Optic neuritis study group. The 5-year risk of MS after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Neurology 1997; 49: 1404–1413
   PubMed Web of Science ®Google Scholar
• Weinshenker B G, Bass B, Rice G P, et al. The natural history of multiple sclerosis: A geographically based study, 2: Predictive value of the early clinical course. Brain 1989; 112: 1419–1428
   PubMed Web of Science ®Google Scholar
• Parkin P J, Hierons R, McDonald W I. Bilateral optic neuritis. A long-term follow-up. Brain 1984; 107: 951–964
   PubMedGoogle Scholar
• Sanderberg-Wollheim M, Bynke H, et al. A long-term prospective study of optic neuritis: Evaluation of risk factors. Ann Neurol. 1990; 27: 386–393
   Google Scholar
• Pirko I, Blauwet L K, Lesnick T G, et al. The natural history of recurrent optic neuritis. Arch Neurol. 2004; 61: 1401–1405
   PubMedGoogle Scholar
• Optic Neuritis Study Group. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 2003; 121: 944–949
   PubMedGoogle Scholar
• Morrissey S P, Miller D H, Kendall B E, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993; 116: 135–146
   PubMedGoogle Scholar
• Optic neuritis study group. The 5-year risk of MS after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Neurology 1997; 49: 1404–1413
   PubMed Web of Science ®Google Scholar
• Söderstrom M, Ya-Ping J, Hillert J, et al. Optic neuritis. Prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 1998; 50: 708–714
   PubMed Web of Science ®Google Scholar
• Tintore M, Rovira A, Rio J, et al. Is optic neuritis more benign than other first attacks in multiple sclerosis?. Ann Neurol. 2005; 57: 210–215
   PubMed Web of Science ®Google Scholar
• Barkhof F, Filippi M, Miller D H, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120: 2059–2069
   PubMed Web of Science ®Google Scholar
• McDonald W I, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50: 121–127
   PubMed Web of Science ®Google Scholar
• Polman C H, Reingold S C, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.”. Ann Neurol. 2005; 58: 840–846
   PubMed Web of Science ®Google Scholar
• Korteweg T, Tintore M, Uitedhaag B, et al. MRI criteria for dissemination in space in patients with clinically isolated syndromes: A multicentre follow-up study. Lancet Neurol. 2006; 5: 221–227
   PubMedGoogle Scholar
• Rocca M A, Agosta F, Sormani M P, et al. A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol. 2008; 255: 683–691
   PubMed Web of Science ®Google Scholar
• Swanton J K, Fernando K, Dalton C M, et al. Modification of the MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry. 2006; 77: 830–833
   PubMed Web of Science ®Google Scholar
• Swanton J K, Rovira A, Tintore M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: A multicentre retrospective study. Lancet Neurol. 2007; 6: 677–686
   PubMed Web of Science ®Google Scholar
• Poser C M, Brinar V V. Problems with diagnostic criteria for multiple sclerosis. Lancet. 2001; 358: 1746–1747
   Google Scholar
• Korteweg T, Uitdehaag B MJ, Knol D L. Interobserver agreement on the radiological criteria of the International Panel on the Diagnosis of Multiple Sclerosis. Eur Radiol. 2007; 17: 67–71
   Google Scholar
• Wattjes M P, Harzheim M, Lutterbey G G, et al. Does high field MRI allow an earlier diagnosis of multiple sclerosis?. J Neurol. 2008; 255: 1159–1163
   PubMed Web of Science ®Google Scholar
• Swanton J K, Fernando K, Dalton C M, et al. Is the frequency of abnormalities on magnetic resonance imaging in isolated optic neuritis related to the prevalence of multiple sclerosis? A global comparison. J Neurol Neurosurg Psychiatry. 2006; 77: 1070–1072
   PubMed Web of Science ®Google Scholar
• Iannucci G, Tortorella C, Rovaris M, et al. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. Am J Neuroradiol. 2000; 21: 1034–1038
   PubMed Web of Science ®Google Scholar
• Fernando K TM, Tozer D J, Miszkiel K A, et al. Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2005; 128: 2911–2925
   PubMed Web of Science ®Google Scholar
• Rocca M A, Agosta F, Sormani M P. A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol. 2008; 255: 683–691
   PubMed Web of Science ®Google Scholar
• Frederiksen J L, Petrera J, Larsson H B, et al. Serial MRI, VEP, SEP, and biotesiometry in acute optic neuritis: Value of baseline results to predict the development of new lesions at one year follow up. Acta Neurol Scand. 1996; 93: 246–252
   Google Scholar
• Simo M, Barsi P, Aranyi Z. Predictive role of evoked potential examination in patients with clinically isolated optic neuritis in light of the revised McDonald criteria. Mult Scler. 2008; 14: 472–478
   Google Scholar
• Sastre-Garriga J, Tintore M, Rovira A, et al. Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: Cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings. Mult Scler. 2003; 9: 39–43
   PubMedGoogle Scholar
• Nilsson P, Larsson E M, Maly-Sundgren P, et al. Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J Neurol. 2005; 252: 396–402
   PubMed Web of Science ®Google Scholar
• Söderstrom M, Ya–Ping J, Hillert J, et al. Optic neuritis. Prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 1998; 50: 708–714
   PubMed Web of Science ®Google Scholar
• Tintore M, Rovira A, Brieva L, et al. Isolated demyelinating syndromes: Comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS. Mult Scler. 2001; 7: 359–363
   PubMedGoogle Scholar
• Jin Y P, de Pedro-Cuesta J, Huang Y H, et al. Predicting multiple sclerosis at optic neuritis onset. Mult Scler. 2003; 9: 135–141
   Google Scholar
• Polman C H, Kappos L W, Freedman M S, et al. Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b. J Neurol. 2008; 255: 480–487
   Google Scholar
• Rolak L A, Beck R W, Paty D W, et al. Cerebrospinal fluid in acute optic neuritis: Experience of the Optic Neuritis Treatment Trial. Neurology 1996; 46: 368–372
   PubMed Web of Science ®Google Scholar
• Cole S R, Beck R W, Moke P S, et al. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Neurology 1998; 51: 885–887
   PubMedGoogle Scholar
• Tintoré M, Rovira A, Río J, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. Neurology 2008; 70: 1079–1083
   PubMed Web of Science ®Google Scholar
• Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med. 2003; 349: 139–145
   PubMed Web of Science ®Google Scholar
• Kuhle J, Pohl C, Mehling M, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med. 2007; 356: 371–378
   PubMed Web of Science ®Google Scholar
• Lim E T, Berger T, Reindl M, et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler. 2005; 11: 492–494
   PubMed Web of Science ®Google Scholar
• Beck R W. The Optic Neuritis Treatment Trial: Three-year follow-up results. Arch Ophthalmol. 1995; 113: 136–137
   PubMedGoogle Scholar
• Achiron A, Barak Y. Multiple sclerosis: From probable to definite diagnosis: A 7-year prospective study. Arch Neurol. 2000; 57: 974–979
   Google Scholar
• Roed H G, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005; 64: 804–810
   PubMed Web of Science ®Google Scholar
• Achiron A, Kishner I, Sarova-Pinhas I, et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis. A randomized, double-blind, placebo-controlled trial. Arch Neurol. 2004; 61: 1515–1520
   PubMed Web of Science ®Google Scholar
• Jacobs L D, Beck R W, Simon J H, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000; 343: 898–904
   PubMed Web of Science ®Google Scholar
• Comi G, Fillipi M, Barkhof F, et al. Effect of early treatment on conversion to definite multiple sclerosis: A randomised study. Lancet 2001; 357: 1576–1582
   PubMed Web of Science ®Google Scholar
• Kappos L, Polman C H, Freedman M S, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242–1249
   PubMed Web of Science ®Google Scholar
• CHAMPIONS Study Group. IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66: 678–684
   PubMed Web of Science ®Google Scholar
• Kappos L, Freedman M S, Polman C H, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389–397
   PubMed Web of Science ®Google Scholar
• Comi G, Carrá A, Fazekas F, et al. Treatment with glatiramer acetate delays conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome: Subgroup analyses. Proc World Congress of Treatment and Research in Multiple Sclerosis 2008; P32
   Google Scholar
• Pittock S J, Weinshenker B G, Noseworthy J H, et al. Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol. 2006; 63: 611–614
   PubMedGoogle Scholar
• Frohman E M, Havrdova E, Lublin F, et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol. 2006; 63: 614–618
   PubMedGoogle Scholar
• Frohman E M, Van Den Noort S. To treat, or not to treat. The therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes. Arch Neurol. 2000; 57: 930–932
   PubMed Web of Science ®Google Scholar
• Balcer L J. Optic neuritis. N Engl J Med. 2006; 354: 1273–1280
   PubMed Web of Science ®Google Scholar
• Dorfman L. Optic neuritis. N Engl J Med. 2006; 355: 212
   Google Scholar
• Coles A. The fragile benefit of BENEFIT. Lancet Neurol. 2007; 6: 753–754
   Google Scholar
• Thompson A J, Hobart J C. Multiple sclerosis: Assessment of disability and disability scales. J Neurol. 1998; 245: 189–196
   PubMed Web of Science ®Google Scholar
• Horton J C. Mistaken treatment of anterior ischemic optic neuropathy with interferon β-1a. Ann Neurol. 2002; 52: 129
   Google Scholar
• ABN. Guidelines for treatment of multiple sclerosis with β-interferon and glatiramer acetate. , et al. Association of British Neurologists, London 2007
   Google Scholar